Outlook Therapeutics (NASDAQ:OTLK) Releases Quarterly Earnings Results, Misses Estimates By $0.04 EPS

Outlook Therapeutics (NASDAQ:OTLK - Get Free Report) issued its quarterly earnings results on Friday. The company reported ($0.89) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.04), Zacks reports.

Outlook Therapeutics Stock Performance

Outlook Therapeutics stock traded down $0.16 during midday trading on Tuesday, reaching $1.71. The stock had a trading volume of 697,307 shares, compared to its average volume of 872,649. The stock has a market capitalization of $54.69 million, a P/E ratio of -0.19 and a beta of 0.58. The firm's fifty day simple moving average is $1.88 and its 200-day simple moving average is $4.41. Outlook Therapeutics has a 1-year low of $0.87 and a 1-year high of $12.85.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on OTLK shares. Chardan Capital restated a "neutral" rating and set a $3.00 target price on shares of Outlook Therapeutics in a research report on Tuesday. HC Wainwright reduced their price target on Outlook Therapeutics from $30.00 to $3.00 and set a "buy" rating on the stock in a research report on Tuesday. Guggenheim reiterated a "buy" rating and issued a $12.00 price target on shares of Outlook Therapeutics in a research report on Friday, January 17th. Finally, BTIG Research reduced their price target on shares of Outlook Therapeutics from $50.00 to $9.00 and set a "buy" rating on the stock in a research report on Friday, November 29th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $12.00.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.